BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 22169654)

  • 1. [Advances in origin and pathogenesis of epithelial ovarian cancer].
    Liu CR; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):569-72. PubMed ID: 22169654
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recent advances on ovarian epithelial cancer: definition, subtypes and pathologic features].
    Guo DH; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):624-8. PubMed ID: 24314254
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].
    Devouassoux-Shisheboran M; Genestie C; Ray-Coquard I
    Bull Cancer; 2016 Mar; 103(3):252-8. PubMed ID: 26853278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 5. [The dualistic model and extraovarian origin theory of ovarian epithelial cancer].
    Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2013 Apr; 48(4):310-3. PubMed ID: 23902820
    [No Abstract]   [Full Text] [Related]  

  • 6. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
    Kurman RJ; Shih IeM
    Hum Pathol; 2011 Jul; 42(7):918-31. PubMed ID: 21683865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
    Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
    Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistence of Brenner tumors with epithelial neoplasia.
    Azoury RS; Mansour ME; Sibai BM
    Gynecol Oncol; 1978 Dec; 6(6):546-64. PubMed ID: 220149
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-grade serous ovarian cancer: A review.
    Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
    Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
    Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
    BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].
    Pozharissky KM; Raskin GA; Vinokurov VL; Yurkova LE; Mukhina MS
    Arkh Patol; 2015; 77(1):38-40. PubMed ID: 25868367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between P53 Protein Expression and Prognosis of Advanced Ovarian Serous Adenocarcinoma].
    Zuo J; Song Y; Li Z; Wu LY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Apr; 38(2):169-74. PubMed ID: 27181893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
    Ahmed N; Abubaker K; Findlay J; Quinn M
    J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezrin overexpression by transformed human ovarian surface epithelial cells, ovarian cleft cells, and serous ovarian adenocarcinoma cells.
    Fadiel A; Chen Z; Ulukus E; Ohtani K; Hatami M; Naftolin F
    Reprod Sci; 2012 Aug; 19(8):797-805. PubMed ID: 22477337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coming into focus: the nonovarian origins of ovarian cancer.
    Dubeau L; Drapkin R
    Ann Oncol; 2013 Nov; 24 Suppl 8(Suppl 8):viii28-viii35. PubMed ID: 24131966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The origin of stroma surrounding epithelial ovarian cancer cells.
    Akahane T; Hirasawa A; Tsuda H; Kataoka F; Nishimura S; Tanaka H; Tominaga E; Nomura H; Chiyoda T; Iguchi Y; Yamagami W; Susumu N; Aoki D
    Int J Gynecol Pathol; 2013 Jan; 32(1):26-30. PubMed ID: 23202778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathogenesis of ovarian clear cell carcinoma.
    Gounaris I; Brenton JD
    Future Oncol; 2015; 11(9):1389-405. PubMed ID: 25952785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.